Related Experiment Video
Updated: Jan 22, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
L J Estcourt1,2
1Radcliffe Department of Medicine and BRC Haematology Theme, John Radcliffe Hospital, Oxford, UK.
Clinical Question:
In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage?
Evidence From Trial:
In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Trial and Error and Algorithm
Statistical Software for Data Analysis and Clinical Trials
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment

